TIDMOPTI
RNS Number : 5247K
OptiBiotix Health PLC
29 August 2023
Opti B i otix Health plc
( "Opti Bi o t ix" or the "Company")
Commercial update
OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness
d e vel o ping co m p o u n ds to tack le o besit y, high choleste
r ol, diabetes and skincare, announces that further to the recent
overview of its SweetBiotix (R) product range announced on 19 July
2023, the Company provides an overview of commercial progress of
its first-generation products range.
T he Company reports an update on commercial activities in 2023
to date:-
I. The Company achieved its highest ever own brand online sales
in July 2023. Online sales growth has been helped by an improved
website, checkout and logistics leading to a 450% increase in the
online conversion rate (number of sales divided by number of
visitors to site), and the opening up of new online channels such
as Amazon. We now have listings of SlimBiome(R) Medical and
Gofigure(R) products on Amazon UK and Amazon Prime, Slimbiome(R)
Medical on Amazon Germany (to be followed by Amazon Prime) and
Walmart USA. We are going through the extensive process of listing
products on Amazon India, Amazon UAE, and Amazon USA as part of the
online internationalisation of our own brand products and
investment in marketing to support further sales growth.
II. One of our partners has secured an international listing for
products containing SlimBiome (R) with Costco, the fifth largest
retailer in the world. Discussions are ongoing to determine launch
plans in a number of territories around the world. Further details
will be provided as products are launched in different
countries.
III. The Company has received a large initial order from a new
partner of GBP116K for SlimBiome (R) from a contract manufacturer
of a leading weight management and sports nutrition brand in the
USA. The company plans to launch in Europe in 2023 followed by a
2024 launch in the USA. Launch plans have high commercial
sensitivity and further information will be provided when approved
by the partner.
IV. We have signed agreements with four new partners in Asia for
SlimBiome(R) since April who have all placed orders. These include
Nasol Pharma International (Vietnam), Bonanaza Neutra Thailand),
Colorinda Chemtra (Indonesia), and NexusWise (Malaysia and
Singapore). These are all well-known specialist distributors in
their field of expertise and are reporting strong interest in
SlimBiome.
V. The Company launched its health and wellbeing WellBiome(R)
functional fibre and mineral blend in May 2023 as part of a
strategy to enhance its range of product offerings. The product has
received excellent reviews on Amazon with growing month on month
sales (125% increase July to August) and a high number of repeat
orders (63% in August). As we move into the Autumn we will increase
our marketing on WellBiome(R) and extend its availability to other
Amazon international channels.
Stephen O'Hara, CEO of OptiBiotix Health plc said: "We are
making good progress on our aims of getting existing partners
returning to forecast, bringing in new partners, particularly in
the USA and Asia, and expanding e-commerce channels to grow online
sales and reduce partner dependency. This is all part of plans for
each business unit (USA, India, Ecommerce, B2B) to reach
operational profitability, at least on a monthly basis by the end
of the calendar year.
"The aim for the second half of the year is to continue our
focus on managing costs, growing sales and closing out ongoing
discussion with a number of larger partners across first and second
generation products to ensure a return on investment from our
expansion in our commercial and business development team."
This announcement contains information which, prior to its
disclosure, was considered inside information for the purposes of
the UK Market Abuse Regulation and the Directors of the Company are
responsible for the release of this announcement.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking
statements. These forward-looking statements are not historical
facts but rather are based on the Company's current expectations,
estimates, and projections about its industry; its beliefs; and
assumptions. Words such as 'anticipates,' 'expects,' 'intends,'
'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions
are intended to identify forward-looking statements. These
statements are not guarantees of future performance and are subject
to known and unknown risks, uncertainties, and other factors, some
of which are beyond the Company's control, are difficult to
predict, and could cause actual results to differ materially from
those expressed or forecasted in the forward-looking statements.
The Company cautions security holders and prospective security
holders not to place undue reliance on these forward-looking
statements, which reflect the view of the Company only as of the
date of this announcement. The forward-looking statements made in
this announcement relate only to events as of the date on which the
statements are made. The Company will not undertake any obligation
to release publicly any revisions or updates to these
forward-looking statements to reflect events, circumstances, or
unanticipated events occurring after the date of this announcement
except as required by law or by any appropriate regulatory
authority.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Neil Davidson, Chairman Contact via Walbrook below
Stephen O'Hara, Chief Executive
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
Peterhouse Capital Limited (Broker) Tel: 020 7220 9797
Duncan Vasey / Lucy Williams
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D programme working with
leading academics in the development of microbial strains,
compounds, and formulations which are used as active ingredients
and supplements. More than twenty international food and healthcare
supplement companies have signed agreements with OptiBiotix to
incorporate their human microbiome modulators into a wide range of
food products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDQELFLXVLXBBF
(END) Dow Jones Newswires
August 29, 2023 02:00 ET (06:00 GMT)
OptiBiotix Health (AQSE:OPTI.GB)
過去 株価チャート
から 10 2024 まで 11 2024
OptiBiotix Health (AQSE:OPTI.GB)
過去 株価チャート
から 11 2023 まで 11 2024
